Dose: 0.071 mg/kg
Single Dose: 0.071 (0.071)
Frequency: As recommended.
Route: IM
Instructions: As Required

Dextromoramide (Tartrate) also known as Dextrodiphenopyrine. . It is of Synthetic origin and belongs to Opioid. It belongs to OPIATE agonist pharmacological group on the basis of mechanism of action and also classified in Analgesic pharmacological group.The Molecular Weight of Dextromoramide (Tartrate) is 542.60. Its pKa is 7.1.

Dextromoramide (Tartrate) is contraindicated in conditions like Obstructive airway disease,Hepatic failure.

The severe or irreversible adverse effects of Dextromoramide (Tartrate), which give rise to further complications include Dependence.Dextromoramide (Tartrate) produces potentially life-threatening effects which include Respiratory depression. which are responsible for the discontinuation of Dextromoramide (Tartrate) therapy.The symptomatic adverse reactions produced by Dextromoramide (Tartrate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Nausea, Vomiting, Tachycardia, Constipation, SweatingX, Giddiness.

Dextromoramide (Tartrate) is primarily indicated in conditions like Moderate to severe pain, Neuroleptanalgesia.

No data regarding the interactions of Dextromoramide (Tartrate) was found.

Drug should not be given to Pregnant Mothers, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab, Inj(IV,SC),suppositry Store in a well closed container, .

Dextromoramide therapy should be commence with reduced dosage in the elderly and when there is evidence of impaired hepatic, renal or thyroid function, and should be discontinued gradually if dependence is suspected.